Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Blood Cancer J. 2018 Jul 31;8(8):71. doi: 10.1038/s41408-018-0104-5.

Affiliations

¹ Division of Cellular Therapy, Duke University, 2400 Pratt Street, Durham, NC, 27708, USA. Dharshan.sivaraj@duke.edu.
² Division of Cellular Therapy, Duke University, 2400 Pratt Street, Durham, NC, 27708, USA.
³ Department of Biostatistics and Bioinformatics, 2424 Erwin Road Suite 1102 11086 Hock Plaza, Durham, NC, 27705, USA.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bendamustine Hydrochloride / administration & dosage
Dexamethasone / administration & dosage
Drug Resistance, Neoplasm
Female
Humans
Male
Middle Aged
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality
Recurrence
Retreatment
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives
Treatment Outcome

Substances

Thalidomide
Dexamethasone
Bendamustine Hydrochloride
pomalidomide